Journal
EUROPEAN RESPIRATORY JOURNAL
Volume 41, Issue 4, Pages 853-860Publisher
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09031936.00213911
Keywords
Clinical study; interstitial lung disease; pulmonary hypertension; riociguat; soluble guanylate cyclase
Categories
Funding
- Bayer HealthCare, Berlin, Germany
- Bayer HealthCare, Germany
Ask authors/readers for more resources
We assessed the safety, tolerability and preliminary efficacy of riociguat, a soluble guanylate cyclase stimulator, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In this open-label, uncontrolled pilot trial, patients received oral riociguat (1.0-2.5 mg three times daily) for 12 weeks (n=22), followed by an ongoing long-term extension (interim analysis at 12 months) in those eligible (n=15). Primary end-points were safety and tolerability. Secondary end-points included haemodynamic changes and 6-min walk distance (6MWD). Overall, 104 adverse events were reported, of which 25 were serious; eight of the latter were considered drug-related. After 12 weeks of therapy, mean cardiac output increased (4.4 +/- 1.5 L.min(-1) to 5.5 +/- 1.8 L.min(-1)), pulmonary vascular resistance (PVR) decreased (648 +/- 207 dyn-s(-1).cm(-5) to 528 +/- 181 dyn.s(-1).cm(-5)) and mean pulmonary artery pressure (mPAP) remained unchanged compared with baseline. Arterial oxygen saturation decreased but mixed-venous oxygen saturation slightly increased. The 6MWD increased from 325 +/- 96 m at baseline to 351 +/- 111 m after 12 weeks. Riociguat was well tolerated by most patients and improved cardiac output and PVR, but not mPAP. Further studies are necessary to evaluate the safety and efficacy of riociguat in patients with PH-ILD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available